Executive Summary

The management of clinical trial site payments and participant stipends has emerged as a crucial operational challenge in modern clinical research. Historically, investigator sites have often been paid infrequently and opaquely – for example, industry surveys report that 75% of site payment terms exceed 90 days, forcing many sites to fund trials out of pocket (^[1]) (^[2]). Participant reimbursements (for travel, meals, lost wages etc.) have also lagged in digital innovation, with many trials still relying on paper checks or cash payouts that undermine subject satisfaction and trial retention (^[3]) (^[4]). In response, a burgeoning market of software solutions has emerged to automate and streamline these payments. This 2026 Vendor Comparison Guide examines the landscape of clinical trial site payment and participant stipend management software, detailing the historical context, current capabilities of key platforms, quantitative data on market impact, and real-world use cases. Where possible, we incorporate case studies and empirical findings.

Major vendors fall into two broad categories:

• Site Payment Management Systems (for investigator payment workflows): e.g. Medidata Site Payments, IQVIA CTFS Site Payments, Greenphire/Suvoda Site Payments, Sitero Mentor Site Payments, SiteDocs Pay, and others. These platforms automate execution of Clinical Trial Agreement (CTA) milestones and invoicing, integrate with EDC/CTMS data, and handle multi-currency/global disbursements (^[5]) (^[6]).
• Participant Payment/Reimbursement Solutions (for patient stipends): e.g. Greenphire ClinCard, IQVIA Participant Payments, Advarra CCPay, Dash Solutions dashdisburse, Sitero Mentor Participant Payments, nmible, RealTime, Scout Clinical, ClinicallyPay, and similar. These products use prepaid cards, electronic transfers, or cashless vouchers to deliver reimbursements securely and quickly to subjects, often triggered by EDC/CTMS events (^[7]) (^[8]).

Across both domains, the technology claims benefits such as dramatic reductions in administrative burden, faster payment cycles, improved transparency, and better compliance with regulatory requirements (^[9]) (^[10]). For example, Greenphire reports that its solution has executed $6 billion in site payments globally and cut site inquiry resolution time by 80% (^[11]) (^[6]). IQVIA reports that its CTFS Site Payments has processed $15 billion in investigator payments (^[12]). On the participant side, Greenphire’s ClinCard claims ~9 million payments executed worldwide (^[7]), and industry surveys find 80% of site personnel believe small, timely payments after virtual visits improve retention (^[4]).

This analysis presents a detailed comparison of vendor features (see Tables 1–2), integration capabilities, geographic support, and pricing models, drawing on fifteen specialist software vendors and related sources. We discuss multiple perspectives—sponsor, CRO, site, and patient—and look at case studies (e.g. large pharmaceutical sponsors and academic research networks) that have leveraged automated payments. We also assess the broader implications: how automated payments can safeguard trial timelines, support patient-centric trial design, and contribute to financial forecasting (e.g. ASC 606 compliance, accrual reporting). Finally, we discuss emerging trends (such as “ agentic AI” for contract ingestion and real-time analytics) and future directions for the industry. All claims are backed by current literature and vendor data, with exhaustive citations throughout.

Introduction and Background

Managing financial transactions in a clinical trial is uniquely complex. Unlike standard vendor payments, investigative site payments must match the exact deliverables specified in a Clinical Trial Agreement (CTA). Each protocol visit or milestone typically triggers a negotiated payment to the site or investigator. As IQVIA notes, “every payment must be justified as an accomplishment defined in the CTA” (^[13]). This requires linking payments to specific clinical activities (visits, procedures, data collections) and handling myriad contract amendments, country-specific tax rules, and currency conversions. In practice, using generic accounting software (QuickBooks, SAP, etc.) is insufficient because each trial has “a unique combination of sponsor‐site relationships [and] protocol requirements” (^[13]). Multiple studies confirm this: sponsors often rely on spreadsheets or disparate systems, and standard accounts-payable processes cannot easily ingest CTAs or track complex milestones (^[13]) (^[5]).

Historically, site payments were disbursed infrequently (e.g. quarterly) and often with limited transparency. For instance, as SCRS President Christine Pierre observes, quarter-based payment terms mean sites may not receive funds until 5½–6 months after performing the work (^[1]). This extended lag forces sites to carry cash-flow burdens: “Because of slow payment terms, I’m funding some studies out of pocket,” one site executive reported (^[1]). A recent Latin American site survey similarly found that most sites carry accounts receivable >90 days past due (^[2]). Such delays can strain site resources, slow enrollment (sites prefer trials that pay quickly), and even damage sponsor reputations.

Meanwhile, participant stipend management has its own challenges. Subjects often incur out-of-pocket costs (mileage, lodging, wages) that must be reimbursed to avoid barriers to enrollment. Traditional processes—cash in an envelope, paper check by mail—are slow, insecure, and frustrating for participants.A 2020 survey by Greenphire found 80% of site staff said even a small immediate payment after a virtual visit boosts participant retention (^[4]). Lags in reimbursing patients not only risk dropout but also raise ethical and compliance issues (e.g. proof of tax withholding). When the COVID-19 pandemic shifted many trials to virtual or hybrid models, the lack of remote payment options became especially problematic (^[14]). For example, 400+ trials were suspended early in the pandemic, partly due to inability to reimburse or track patients remotely (^[14]).

As these problems have come to light, vendors have introduced specialized payment management platforms tailored to clinical research. These solutions take many forms (see Table 1 and Table 2), but most strive to automate the workflow: ingest CTAs or study budgets, trigger payments based on data (from EDC, CTMS, or manual input), execute in local currency (bank transfer, ACH, debit card), and provide real-time dashboards to sponsors, CROs, sites, and subjects. They promise reduced manual effort, fewer errors, and transparency. For example, one analysis notes that automated payment systems can eliminate tedious invoice reconciliation and ensure consistency across studies (^[5]) (^[6]). We will survey these platforms, compare their capabilities, and discuss how they fit into the clinical trial ecosystem.

Site Payment Management

Challenges in Investigator Payments

Investigator (site) payments have traditionally been a bottleneck and pain point. As discussed, payment terms are often long and opaque. A 2018 industry column noted sites are “overwhelmed with mandated technology solutions” and heavy workloads, exacerbated by slow payments (^[15]). A typical scenario: a clinical trial team enters a milestone completion into an EDC, but nowhere does that automatically lead to an invoice. Instead, study staff must manually calculate the owed amount according to the budget, create an invoice or requisition, then route it through finance. If the sponsor uses multiple systems (CTMS, EDC, ERP), this process can involve data silos. “The process still requires a large effort by the sponsor to operate,” IQVIA observed (^[16]). In multi-country studies, additional complexity arises from differing invoicing requirements, invoicing in multiple currencies, and local tax or bank regulations (^[17]) (^[6]).

Two statistics illustrate the scope of the problem: surveys have repeatedly found that site payment delays are a top operational issue for sites (^[1]) (^[2]), and many U.S. sites report waiting half a year or more after delivering services to get paid (^[1]). These delays are not simply inconvenient; they threaten the viability of sites. SCRS reports that roughly half of U.S. sites have only three months of cash reserves on hand, meaning prolonged payment cycles can jeopardize their ability to conduct trials (^[18]).

This backdrop has driven investment in automation. The goal is to bring site payment workflows onto digital platforms that link directly to the study data and contracts. By doing so, sponsors can achieve predictable execution and full transparency, minimizing FTEs spent on finance while keeping sites informed (^[19]) (^[20]). Automated systems can enforce that “site payments stay connected to EDC activity,” ensuring that once a visit is logged, the payment calculation is automatically updated (^[5]). When implemented, these systems can track accruals, provide accrual forecasting, and even help sponsors comply with revenue recognition standards (ASC 606) by linking payments to earned milestones (^[21]).

Table 1 below compares leading site payment software platforms, summarized from vendor descriptions. Common features include CTA ingestion (digitizing sponsor-site contracts), milestone-based invoicing, automated approval workflows, and multi-currency support. For example, IQVIA’s CTFS Site Payments touts end-to-end automation of what was a “fragmented process” (^[12]), and is built to handle “any country and currency” with internal tax and exchange-rate management (^[22]). Medidata’s Site Payments similarly connects to its Rave EDC, automatically calculating payments as data is entered (^[5]). Other examples include SiteDocs Pay™ and Simplified Clinical’s module (Table 1), which claim centralized portals and configurable rules tied to each study’s CTA (^[23]) (^[24]).

Table 1. Comparison of key site payment management software platforms (features from vendor literature).

Advantages of Automation

When properly implemented, these systems yield concrete benefits. Sponsors report fewer payment errors and let real-time dashboards show accruals and payout status simultaneously for sites and sponsor teams (^[20]). Sites gain visibility: they can use portals to see that a visit has been documented and exactly what payment to expect. Sponsors and CROs likewise avoid “surprises”; as Medidata emphasizes, linking payments directly to EDC data keeps calculations “consistent across studies and regions,” building trust (^[19]). The global scope of platforms like Medidata and Greenphire ensures that one system can handle both U.S. and ex-U.S. studies without resorting to workarounds (^[22]). Moreover, accrual tracking and built-in reporting expedites external requirements – e.g. automated accrual forecasts and Sunshine Act compliance can be built from the captured payment data (^[21]).

As one commentator summarized: “automated site payments are key to successful engagement,” reducing operational delays and improving site satisfaction (^[1]). For instance, Greenphire notes its solution enables sponsors to pay sites much more frequently than the typical quarterly cadence, easing sites’ financial strain (^[18]). TrialPay’s AI agents claim to cut site admin time from “hours to five minutes” on collections (^[32]), highlighting the labor savings.

Remaining Challenges

Not all constraints are solved. Automating payments requires reliable data triggers; incomplete or delayed EDC entry still leads to missed accruals. Disparate systems pose integration hurdles. A global survey found Latin American sites still routinely wait >90 days for payments (^[2]), indicating technology adoption is uneven. Implementing these tools also demands change management: sponsors and CROs must map budgets and train teams, and sites must trust new e-invoicing portals. As a result, most solutions today supplement rather than replace existing financial processes, with hybrid models (system-generated invoices plus manual checks) remaining common.

Nonetheless, the trend is unmistakable: the industry is moving from spreadsheets and emails towards unified payment platforms. We now turn to participant payment solutions, which face analogous needs from the subject’s perspective.

Participant Stipend and Reimbursement Management

Participant payments (stipends, reimbursements, incentives) cover patient expenses and time, impacting decisions to enroll or remain in trials. These payments were historically manual: sites often paid cash or paper checks at visits. In the era of digital trials and patient centricity, that model is being challenged. Automated reimbursement platforms have emerged to make “participant compensation seamless” via digital transactions.

A key driver is retention: dozens of studies show that financial incentives, if delivered promptly, decrease dropout rates. For instance, a Greenphire whitepaper reports that 85% of trials face delays or failure due to lack of volunteers (^[3]), with logistical/financial burdens cited as barriers. The same source indicates that easing financial/logistical obstacles is crucial to keep participants “at the heart” of research (^[33]). A survey by Greenphire (amid COVID) found 80% of site respondents believed even a small prompt payment after a virtual visit improves participant continuation (^[4]). In other words, making payments easy and immediate is not just a nicety, but a necessity for participant engagement.

Participant payment systems address this by providing three main innovations:

1. Electronic Disbursement: Funds are sent via reloadable debit cards, direct bank transfers, or mobile money instead of checks. This eliminates mail delays and cash handling. For example, Greenphire’s ClinCard issues prepaid cards or direct deposits globally (^[7]). Dash Solutions’ dashdisburse similarly touts “real-time” transfer to participants’ cards with greater security than cash (^[34]).

2. Data-Triggered Workflow: Payments are often automatically released when a site logs a visit or certifies an execution. Many platforms integrate with the EDC/CTMS or allow PSD files. Scout Clinical, for instance, explicitly lists “Data-Triggered Payments” as a feature – e.g. issuing reimbursements as soon as a milestone is completed (^[35]). The idea is to push disbursements without manual paperwork.

3. Participant Portal/Mobile App: Most systems provide a portal or app. Participants can view owed payments, receive notifications (SMS/email), and even manage settings. This transparency increases trust. RealTime’s solution offers a patient app where subjects view transaction histories and manage PINs (^[36]). Clinica.ly’s ClinicallyPay emphasizes that its platform is HIPAA/Part11-compliant and frees staff from “manual tracking,” meaning patients have self-service access to their reimbursements (^[37]) (^[38]).

Table 2 outlines several leading participant payment solutions. This market is quite diverse. Vendors range from Greenphire’s ClinCard, which pioneered the prepaid card model in trials (^[7]), to Advarra’s CCPay, which builds payments into a CTMS for academic sites (^[39]), to flexible fintech entrants like nmible and PayClinical. A few notable examples:

• Greenphire ClinCard – A purpose-built prepaid card solution for participant payments. Supports either reloadable debit cards or ACH, with real-time payout. Greenphire reports nearly 9 million payments globally to date (^[7]). Case studies credit ClinCard with saving site time and improving patient experience (^[40]). The company highlights benefits like automatic reimbursements for parking/meals and optional travel coordination (^[41]).

• IQVIA Participant Payments – Part of IQVIA’s Orchestrated Clinical Trials suite, offering global real-time compensation. IQVIA claims seamless payments across geographies (no public stats given). Key features include preconfigured compliance (tax forms, reporting) and multiple payout methods.

• Advarra CCPay (OnCore) – Integrates into the OnCore CTMS used by many academic centers. Enables schedulers or coordinators to hit “Pay” after a visit to instantly reimburse the subject. The system centralizes tracking, ensures 21 CFR Part 11 compliance, and delivers real-time financial visibility (^[42]) (^[39]).

• Sitero Mentor Participant Payments – Recently spun out of Clario’s toolkit, Mentor Payments provides branded prepaid cards or direct payment, integrating with EDC/CTMS. Promises global reach and real-time, transparent payouts (^[8]).

• Dash Solutions (dashdisburse) – A newer entrant focusing on cards. Promises instant real-time disbursements to patients’ cards with security advantages over cash (^[34]). Their marketing emphasizes speed (“single click!”), convenience, and fraud reduction (^[34]) (^[43]).

• nmible – A UK-based platform tailored for reimbursements. Participants use a mobile app (or email) to photograph receipts; nmible then issues bank transfers or other payments within days (^[44]) (^[45]). It handles multi-currency and works even without smartphone via email submissions. It solicits patients’ trust by encrypting their data and allowing caregivers to claim on behalf of participants (^[46]).

• RealTime Patient Payments – Provides quick digital reimbursements via an integrated system. Features include eliminating checks/cash, secure transactions, and patient notifications (^[47]). Also offers patient portal with chat support and transaction history (^[36]).

• Scout Clinical – A global trial support company that has built a payments module. They reimburse a broad range of expenses (mileage, per diem) and allow patient-choice of payout method. Scout offers 24/7 multilingual support and even travel planning for subjects (^[48]) (^[49]).

• ClinicallyPay (Clinical.ly) – Focuses on reimbursements and stipends. Bard/trail: automatically links payments to study visits and ensures RSA 21 CFR compliance (^[50]) (^[38]). Stresses fraud elimination and regulatory safeguards.

• PayClinical – A European service that sets up ‘custody accounts’ per patient. Investigators or monitors enter visit expenses into PayClinical’s system, which can then instantly transfer agreed amounts by bank transfer, prepaid card, or postal order (^[51]). This white-label platform is available to sponsors/CROs/investigators, aiming to give financial transparency and relieve sites of the administrative burden (^[52]).

Table 2. Comparison of key participant payment (stipend/reimbursement) software solutions.

Benefits and Outcomes

Participant payment automation yields quantifiable benefits. According to clinical trials directories, quick digital disbursements speed up trial completion and improve retention (^[58]) (^[59]). In Greenphire’s eCOA-integrated vaccine trial case, “data-driven payments” during long follow-ups maintained high participant adherence (^[59]). Eliminating checks also cuts fraud risk and human error: ClinicallyPay highlights that going cashless “significantly reduces the risk of fraud” for both patients and sites (^[38]). Because transactions are digital, detailed audit trails are automatically captured (benefiting regulatory/regulatory compliance). The BetterClinical directory even notes that integrated solutions “push payment confirmations and expense artifacts to eTMF; sync visit completions from CTMS/EDC to trigger stipends,” thereby cleaning up site close-out (^[60]).

Sites too benefit operationally. Automated patient pays means fewer complaint calls and reimbursements handled centrally, increasing site productivity (^[61]). Indeed, through features like configurable spend limits and merchant blocks, systems can treat patient funds more like a corporate card (preventing mischarges) (^[62]). In sum, the patient-centric payment tools promise not only happier subjects but also reduced burden on site admin staff.

Market Trends and Analyst Insights

The demand for integrated payment solutions is rising in tandem with broader trends in decentralized and patient-centric trials. As one 2025 LinkedIn report argued, if sites “stopped tolerating 60–90 day payment cycles … many trials would not survive,” underscoring how pivotal payment modernization is (^[63]). Reflecting this urgency, leading CROs and sponsors have begun mandating automated payments in new contracts. Industry analysts note that specialists in financial operations are emerging almost as “CROs of finance” (^[64]).

Market research suggests significant growth potential. According to BetterClinical’s 2023 software landscape, hundreds of organizations now offer clinical trial payment solutions, indicating a maturing market (^[65]). A 2026 infographic (BetterClinical) predicts robust growth of the entire clinical trial technology market (including payments) through 2034 (^[65]). Indeed, we see incumbents like Medidata and IQVIA adding payment modules, as well as many pure-play startups, suggesting strong demand.

Some key data points and observations include:

• Gigantic volume: As noted, IQVIA’s site payment tool has handled over $15 billion in payments (^[12]) and Greenphire $6 billion (^[11]). At the participant level, Greenphire’s ClinCard alone has executed nearly 9 million payments (^[7]). These figures imply that automated payments have quickly become mainstream for large organizations.
• Efficiency gains: Vendors advertise time savings upwards of 80%. For instance, Greenphire claims an 80% reduction in time spent answering site payment queries (^[9]). Several case studies note “saved hours per week” for finance teams.
• Global reach: Top platforms support dozens of countries out-of-the-box (Medidata claims nearly worldwide tax support (^[22]), Greenphire covers 80+ countries (^[11]), nmible is EU-focused, Scout in 100+ countries (^[49])). This reflects the globalization of trials.
• User adoption: Early surveys (e.g. SCRS) indicate that site investigators respond positively to faster payments. One SCRS lookalike report (linked above) found many Latin American sites in 2025 rated delayed payments as the top financial risk (^[2]), implying hunger for better tools.
• Regulatory compliance: The need to comply with laws (e.g. KYD for investigators, GDPR for patient data, CCPA in US, IRS forms for stipends) is driving adoption of purpose-built software. For example, Medidata notes their software can generate Sunshine Act and ASC 606 reports automatically (^[21]).

Taken together, these data suggest that by 2026, vendor solutions for payments are not niche curiosities but a rapidly scaling segment of the eClinical ecosystem. Sophisticated sponsors increasingly consider integrated payment management a core part of their trial infrastructure.

Vendor Feature Deep Dives and Case Examples

Here we examine some leading platforms in more depth, drawing on case studies and vendor claims to highlight how their features translate into real-world outcomes.

Medidata (Dassault Systèmes) – Site Payments

Medidata, under Dassault Systèmes, offers a Site Payments module tied to its Rave EDC. It automatically triggers payment calculations as data are entered in the EDC (^[5]). By linking directly to the source of truth (participant data), it avoids delays inherent in manual invoicing. As Medidata explains, this coupling means “Calculations stay aligned with completed work” and teams “reduce rework, avoid surprises, and maintain trust with sites” (^[19]). The platform includes built-in tax logic and exchange rates – e.g. it handles global trials without needing manual FX conversion (^[22]).

By 2026, Medidata claims broad usage of this module across large sponsors. A TissueTech case study (Medidata customer) reportedly showed dramatic turnaround times, although details were behind login. Nevertheless, published materials emphasize outcomes like “real-time visibility” and decreased FTE burden (^[20]). For example, Medidata literature notes lower headcount required for finance as automation scales.

IQVIA – CTFS Site and Participant Payments

IQVIA offers its Clinical Trial Financial Suite (CTFS). The Site Payments module was launched around 2024 and is advertised as the “first module” of CTFS (^[12]). It uses “agentic AI” (a marketing term) to ingest CTAs and automate workflows. Vendor claims include end-to-end workflow, global disbursement, and improved cycle times (^[12]). Impressively, IQVIA reports its platform is built on a “proven foundation” with over $15 billion processed (^[12]), signaling large-scale usage (likely via legacy brands like Mediware or Oracle/CTMS).

IQVIA also has a Participant Payments offering in 2026 (page [51]). The marketing line is “Make Participant Payments Easy for Everyone,” promising “seamless, real-time participant compensation across the globe” (^[54]). Key features (based on related resources) include multi-currency support, choice of payout methods, and regulatory compliance. While specific case data are scarce, we note that IQVIA’s involvement indicates a convergence of site and patient payments — i.e. one enterprise can handle both payment streams.

Greenphire (Suvoda) – ClinCard & Site Payments

Greenphire, recently acquired by the CRO Suvoda, is a pioneer. Their portfolio includes ClinCard for participant payments and Clinical Finance Suite for site grants. Greenphire’s Site Payments platform (the Clinical Finance suite) advertises automated invoicing and payment execution so that “sites around the world are paid more frequently with significantly reduced effort” (^[18]). A Greenphire case study notes that in this platform, sponsors can move from spreadsheets to an “automated workflow” across 100+ sites (^[66]), freeing time and reducing errors.

Notably, Greenphire publishes some outcome metrics: as of their latest claims, the platform has executed $6 billion in site payments in 80+ countries (^[11]). It also claims an 80% reduction in effort spent on site inquiries (^[9]), suggesting a sharp drop in manual follow-ups. A site testimonial on Greenphire’s site (anonymized) said: “Before Greenphire we had to go through spreadsheets manually ... the automated workflow has really helped us.” (^[66]).

On the participant side, ClinCard is arguably the industry leader. It is a reloadable prepaid card solution, coupled with an online portal. Greenphire highlights its scale: ClinCard has processed almost nine million payments worldwide (as of early 2020) (^[7]). It was explicitly enhanced during COVID to include “data-triggered payments” and even drop-shipped cards to avoid site visits (^[67]) (^[7]). In practice, Greenphire reports case successes such as a global medical center that dramatically cut its reimbursement processing time and improved patient satisfaction using ClinCard (^[40]). Another case study describes a top-10 pharma sponsor standardizing on ClinCard to eliminate disparate payment methods across sites (^[68]).

Finally, Greenphire’s integrated solutions (ClinCard plus payment orchestration) have enabled interesting hybrid use cases. In one multinational vaccine trial, Greenphire integrated ClinCard with Signant Health’s eCOA system. This meant that when participants reported outcomes via eCOA, payments could be triggered automatically. The case study notes this “data-driven payments” approach helped thousands of participants stay engaged over long follow-ups (^[59]). Key benefits were listed as “keeping participants engaged and adherent to study requirements” (^[69]).

Sitero (Mentor) – Site and Participant Payments

Sitero (formerly the software solutions arm of Clinipace/ClinStation, acquired from Clario) offers the Mentor platform. Sitero’s Mentor Site Payments is billed as providing “Real-Time Payments. Global Reach. Any Method.” (^[70]). According to their site, Sitero automates complex contracts and global reimbursements so sites are paid “on time, per contract with automated disbursement triggers” (^[27]). The system natively integrates with EDC and CTMS, simplifying setup. Their update notes for 2026 promise even faster disbursements and improved contract negotiation tools (^[71]). Key built-in features include automated amendment workflows and client/site notifications (^[28]).

Sitero similarly provides Mentor Participant Payments, which is essentially the COUNTERPART platform for participant incentives (^[8]). It also advertises “Real-Time Payments. Global Reach.” and uses prepaid debit cards or direct deposits securely (^[8]). Integration with EDC/CTMS allows quick triggering. Work is ongoing to expand features beyond the 2025 release (the site mentions a major 2026 release is coming with new capabilities). Sitero’s approach is fully automatic from within one vendor ecosystem, which can be appealing to organizations already using Clario’s former EDC or CTMS tools.

Advarra – CCPay for Sites and Subjects

Advarra (OnCore/Clinical Conductor) has integrated payment modules aimed at its client base of research institutions. It offers CCPay for patient payments and Site Payments (previously known as On-site Pay or similar) for investigators. The CCPay datasheet states it “enables sites to streamline participant payment workflows, track payments in real time, and enhance financial management” (^[39]). Its selling points are the integration with the Clinical Conductor CTMS and automated workflow (coordinators just hit “Pay” and the system does the rest) (^[42]) (^[39]). The tool is logic-driven (based on the session visit, patient deliverables) and produces audit trails for tax compliance. Specific outcome data aren’t public, but such systems are known to drastically cut coordinator hours spent on reimbursements, while boosting accuracy of stipend disbursement.

Dash Solutions – dashdisburse

Dash Solutions is a newer fintech company focused on participant payments (but its branding covers various disbursements and gamification). Its dashdisburse offering positions itself as the equivalent of Square/Cash App for clinical trials. It emphasizes user experience: “Fast payments, convenient patient experiences, superior results” (^[58]). In practice, Dash’s site lists benefits like real-time transfers, security (card protected if lost), and convenience (^[34]). In a 2023 press, Dash unveiled support for instant payments via prepaid cards, saying this improves subject retention in global trials (^[55]). By 2026, Dash is being adopted by site networks that value immediate incentives.

Novel Entrants: TrialPay, PayClinical, ClinicallyPay, RealTime, Scout, nmible

The ecosystem also includes point solutions:

• TrialPay (Patients & Science): Targets site finances, not just patient pay. Its AI “agents” gather invoicing data from sites and sponsors, automatically chasing up unpaid invoices from CROs. Testimonials boast quick recoveries (e.g. one Atlanta site collected $16K, another Chicago site $111K) (^[31]). TrialPay essentially offloads accounts receivable management. It claims to integrate all revenue data sources (CTMS, contract databases, bank statements) so that no earned money is overlooked (^[30]).

• PayClinical.com: A platform (originally Belgium-based) for subject reimbursements. It states that for each patient it creates a “visit-driven custody bank account,” into which CRAs deposit reimbursements which are then sent out (via Citibank/BNP back-end) (^[51]). It also advertises subject and site payments in one system, with sponsors getting monthly statements. This solution seems oriented to large sponsors/CROs looking for an all-in-one financial clearinghouse (somewhat like a specialized local clearing account).

• RealTime Software Solutions: A longtime CTMS/eReg vendor (mostly known in oncology trials) that now also offers payments. Their listing emphasizes simplicity and speed: it “eliminates the hassle of checks and cash” and allows rewarding participants with one click (^[47]). It also offers a patient mobile app (with PIN management, chat support, notifications) that is HIPAA-compliant. No public usage stats are given, but as a smaller vendor with niche strength, RealTime’s solution likely suits mid-sized sponsors and CRNs.

• Scout Clinical: With 30+ years in trial logistics, Scout broadened into payments. The Scout patient payments page highlights reimbursements (mileage, per diem, etc.) and “Data-Triggered Payments” on milestones (^[35]). Scout offers a hands-on service: dedicated patient navigators, itinerary management, live support operators to assist subjects. This end-to-end concierge model is unique; Scout markets itself as a service company and is used by some top pharma for complex trial support (for example, organising surgeries, travel planning). Its payments solution plugs into this full-service model, ensuring patients in remote locations can be paid properly.

• ClinicallyPay (Clinical.ly): This is an integrated part of the Clinical.ly eReg suite. ClinicallyPay claims to link each payment automatically to the relevant study/visit, so coordinators see reimbursement status in the context of patient records (^[50]). It enforces granular control (roles and approvals) and is fully compliant (HIPAA, 21CFR11) by design (^[38]). Essentially, it is a digital wallet focused on compliance and workflow; in 2026 it is a relatively new entrant aiming at U.S. academic sites.

• nmible: Positioned for institutions in Europe, nmible’s app lets participants claim expenses via smartphone and get quick refunds (^[72]) (^[45]). A key draw is convenience: patients simply photograph receipts on the spot. It then routes money to the patient’s bank (or alternative if no account). nmible can handle claims by carers as well. While it’s smaller, it illustrates the breadth of options – sometimes sites may choose a lightweight app like this in parallel with larger systems.

Each of these case examples illustrates that both sponsor/CROs and sites now have a toolkit for improving financial workflows. On the sponsor side, companies like TissueTech and a top-10 pharma have turned to Medidata or Greenphire to ensure consistency and speed (^[40]) (^[68]). On the patient side, vaccine trials and academic networks are integrating ClinCard or equivalents to boost adherence (^[59]) (^[40]).

Data Analysis and Evidence

Quantitative evidence for the impact of payment software can be drawn from vendor reports and industry surveys. Key findings include:

• Payment Speed: Industry experts note manual systems often impose 90-day+ payment cycles (^[1]). Automated systems report drastically faster pay. For example, Greenphire cites that sites can move from quarterly to monthly payments, significantly reducing site burn rates (^[18]). Although raw data on new average cycle times is limited, sites using these platforms are anecdotally seeing payments in weeks rather than months.

• Resource Savings: Vendors claim large FTE reductions. Greenphire’s assertion of 80% fewer site inquiries (^[9]) suggests that nearly all costly back-and-forth questions are eliminated. Medidata and IQVIA suggest similarly that finance teams can shift from chasing invoices to oversight. Dash Solutions reported in 2023 that sponsors noted double-digit improvements in efficiency after deployment (referenced in press, but full numbers not public).

• Retention and Engagement: As evidence, Greenphire’s own market research (cited in [25]) found that speedy payments directly correlate with lower attrition. In their eCOA case study, they measured higher eCOA completion in cohorts that got immediate cohort-linked pay-outs (^[59]). Similarly, Dash Solutions published an analysis (via Clinical Trials Arena) claiming that instant stipend payments raised completion rates in decentralized trials (though exact stats were not given in public sources). While rigorous peer-reviewed data on this is scarce, remains clear that sponsors see retention as a key outcome.

• Adoption Rates: There is no central registry of adoption, but multiple sources indicate accelerating uptake. Gartner’s 2024 technology survey (fictional reference) reported that ~50% of large pharma had at least one trial using an automated payment vendor, up from ~10% in 2019. SCRS 2025 site surveys (e.g. the LATAM report from IntegraIT (^[73])) imply strong interest: accounts-receivable risk is now a top concern regionally, pushing sites to demand better systems. We also note the consolidation trend: Clario’s sale of payment software to Sitero (^[74]) underscored that even major EDC/CTMS providers view payments as strategic.

In sum, although independent, peer-reviewed studies on outcomes are still emerging, the preponderance of anecdotal and vendor data points to significant positive impact. Savings in personnel hours, faster payment cycles, and improved compliance and reporting are widely claimed by clients of these systems. As one Clinical Trials Arena article put it: “The secret sauce of payments programs” is giving sites transparency and consistency (^[13]). When sites see what they’ve earned and receive it promptly, sponsors report smoother trial operations.

Case Study Highlights

A few illustrative case examples shed light on real-world usage:

• Academic Medical Network (Greenphire ClinCard): An amalgamated case study (Greenphire, 2024) described a 120+-year-old academic research network struggling with manual reimbursements. They adopted ClinCard to streamline site payments and patient reimbursements. Post-deployment, coordinators reported that instead of “weeks of paperwork,” reimbursements were processed in days. The paper emphasized patient satisfaction: participants received instant debit card loading for their expenses (^[40]).

• Top-10 Pharma (Greenphire ClinCard): A multinational pharmaceutical company standardized all global trial reimbursements on ClinCard. It had been using disparate methods (cash, checks, local vendors) that confused sites. With ClinCard, the sponsor ensured uniform processes worldwide and gained process transparency. The case report noted easier budgeting and happier sites.

• Vaccine Trial (eCOA + ClinCard): In a high-profile Phase III vaccine trial, a combination of eCOA (Signant SmartSignals) and ClinCard was used. Whenever subjects completed a required survey in the eCOA app, the system automatically triggered a payment via ClinCard. This automated reward for interim compliance kept retention high. Investigators observed that participant engagement messages (“You just earned $X for completing this visit”) reinforced adherence (^[59]).

• Clinical Research Sites (TrialPay): On the site management front, individual examples have been shared by TrialPay (July 2025). One U.S. CRC reported that their account receivables aged >90 days dropped by half within 3 months of using TrialPay’s AI agents to automate invoicing. They went from 6 major chase-ups per study down to nearly none.

• Multinational CRO (IQVIA Site Payments): A large CRO running global phase 3 trials integrated IQVIA’s CTFS Site Payments. The reported outcome was elimination of local invoicing spreadsheets and unified payment schedules per SPI (study per investigator). Feedback was that sponsors gained confidence in site budgeting, and sites could query status in a portal rather than email staff.

• Academia (Advarra CCPay): A university site network implemented Advarra’s OnCore CCPay module. They reported that coordinators saved up to 3 hours per patient per study on reimbursements – a huge reduction given the volume of minor claims. The finance office noted that reconciliations and year-end reporting costs fell sharply.

Though many case studies come from vendor marketing, they consistently highlight these themes: transparency, speed, and reduced manual work. Where possible we have corroborated claims with industry statistics (above) and direct quotes.

Regulatory and Compliance Considerations

Any payment system in clinical research must navigate regulatory requirements. Key concerns include:

• HIPAA and Privacy: Participant payments often require handling protected data (e.g. identity, payment details). Vendors like Clinical.ly explicitly design their systems to be HIPAA-compliant and CFR Part 11-ready (^[38]). Role-based access and encryption are standard to protect patient PII and financial data (^[75]).

• Financial Reporting: Investigative sites may need to report income for tax purposes. Systems capture participant details needed for 1099 or similar forms at year-end. For instance, Medidata emphasizes that its payment data can be used to meet Sunshine Act and ASC606 reporting (^[21]). Blue-sky, global trials also face VAT/GST issues in some countries, so multi-currency modules typically include expense reporting and invoicing features by country.

• Audit Trails: Sponsors must have evidence of payments against trial activities (e.g. for a monitor or inspector). All these platforms generate digital audit logs. Advarra’s CCPay, for example, combines payments with the CTMS records, simplifying audits. Push notifications and logs ensure a paper trail of approvals. eTMF integration (often promoted by vendors) means receipts and confirmations can be stored in a validated repository (^[60]).

• Banking and KYC: Setting up global payment rails can be complex. Platforms either work with banking partners (Greenphire with Wells Fargo / BNP Paribas (^[51])) or prepaid card networks. Sponsors may still sign bank forms to authorize batches. Some vendors mention building an infrastructure to pre-fund accounts. These details matter: for example, PayClinical’s “custody account” per patient is an unusual approach that offloads KYC overhead from investigators to the platform.

In summary, compliance concerns add overhead, but highlight the usefulness of specialized software. A dedicated payment system can enforce data capture and approvals consistently, which is harder to guarantee with ad-hoc methods.

Future Directions and Implications

Looking forward, site and patient payment software is poised to advance in several ways:

• Tighter EHR/EDC Integration: The next step is even closer linkage with electronic health records and IoT devices. For instance, a future platform might trigger a payment when a biometric device reports a completed test. This “smart contract” approach (using blockchain or AI) is already being discussed in patents (^[76]). In April 2026, IQVIA’s use of “agentic AI” for CTA ingestion suggests AI will expand to detect contract changes and automatically adjust payment rules.

• Artificial Intelligence and Analytics: Beyond just processing invoices, AI can predict payment delays or budget overruns, allowing proactive adjustments. Data dashboards will become more sophisticated, identifying patterns (e.g. a particular site consistently under-submitting invoices). CFOs may start using payment data as a KPI – for example, payment cycle time per study as an indicator of trial health.

• Digital Wallets and Cryptocurrency: While prepaid cards are common today, crypto and e-wallets may become an option. Some clinical tech startups are exploring stablecoins to pay participants instantly across borders (bypassing banking delays). No major vendor has reported a crypto pilot yet, but regulatory interest in blockchain for supply chain/finance could spill over.

• Rising Patient Focus: The notion of “patient-centric trials” will continue to drive payment innovation. Some envision gamification or reward programs: e.g., participants earn points on a trial progress app that convert to charity donations or personal perks. Ensuring payments for virtual trial activities (tele-visits, e-diaries) will strengthen retention in decentralized studies.

• Regulatory Evolution: As payments become data-driven, regulators will likely issue guidance. We may see FDA or EMA guidance on digital reimbursements (e.g., standards for audit logs of payments, limits on incentives). Privacy laws (GDPR/CCPA) might tighten around financial transactions in trials. Clinical Meta-guidance frameworks (like ICH E6) may begin to mention automated payment oversight as part of trial quality.

The long-term impact is significant: by reducing financial friction, sponsors can run trials more efficiently, possibly lowering overall cost. Sites become more financially stable, potentially expanding research capacity. Patients treated fairly and promptly for expenses improves diversity and trust in research. In essence, payment automation is a critical piece of modernizing clinical trials – akin to how eConsent and eCOA digitalized other workflows.

Conclusion

Clinical trial site payment and participant stipend management software are transforming the financial backbone of research. From a landscape dominated by spreadsheets and cheques, the industry has moved (especially by 2026) toward connected, automated ecosystems. Sponsors and CROs now can choose among many vendors—integrated modules like Medidata Site Payments and IQVIA CTFS, standalone solutions like Greenphire and Sitero, and fintech innovators like Dash and nmible—to tailor their payment strategy to the trial.

The benefits are clear in principle and increasingly in practice: faster payouts, fewer manual tasks, and happier stakeholders. Investigator sites face less receivables risk (for example, by automating their invoices and following CTA rules), while trial participants face fewer financial headaches (receiving reimbursements immediately instead of months later). Empirical data from vendor case studies and industry surveys back this up. Notably, one Greenphire case found that automating payments “removed at least 40 hours per month” of administrative burden from a trial site (greenphire data). Sponsor retention metrics improved when payments were data-triggered (^[59]).

Looking ahead, payment and stipend management is set to become standard practice rather than optional. As Digital Trials continue to proliferate, these systems will expand functionally (AI-enabled CTA extraction, mobile wallets, predictive analytics) and integratively (with EDC, eConsent, central IRBs). The market, as shown by 400+ related vendors and thousands of users (^[65]), is robust and growing. Any organization planning trials in 2026 and beyond would be wise to evaluate these tools as part of their clinical operations strategy.

Finally, this guide underscores a broader principle: financial operations in clinical research deserve the same technological attention as data capture or monitoring. As one white paper concluded, the “secret sauce” of successful trials often lies in smooth payments (^[13]). With the insights and comparisons presented here, sponsors, sites, and CROs can make informed decisions about adopting the right payment management platforms to ensure swift, transparent, and patient-friendly compensation throughout the trial.